BR9914519A - Peptìdios bioativos estabilizados e métodos de identificação, sìntese e uso - Google Patents

Peptìdios bioativos estabilizados e métodos de identificação, sìntese e uso

Info

Publication number
BR9914519A
BR9914519A BR9914519-7A BR9914519A BR9914519A BR 9914519 A BR9914519 A BR 9914519A BR 9914519 A BR9914519 A BR 9914519A BR 9914519 A BR9914519 A BR 9914519A
Authority
BR
Brazil
Prior art keywords
bioactive peptides
terminus
protein
synthesis
identification
Prior art date
Application number
BR9914519-7A
Other languages
English (en)
Inventor
Elliot Altman
Original Assignee
Univ Georgia Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Georgia Res Found filed Critical Univ Georgia Res Found
Publication of BR9914519A publication Critical patent/BR9914519A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/635—Externally inducible repressor mediated regulation of gene expression, e.g. tetR inducible by tetracyline
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C12N15/72—Expression systems using regulatory sequences derived from the lac-operon
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Patente de Invenção: <B>"PEPTìDIOS BIOATIVOS ESTABILIZADOS E MéTODOS DE IDENTIFICAçãO, SìNTESE E USO"<D>. Um sistema de seleção intracelular permite o rastreamento simultâneo da bioatividade e estabilidade do peptídio. Peptídios recombinantes randomizados são rastreados quanto à bioatividade em um sistema de expressão rigorosamente regulado, de preferência derivado do operon lac do tipo selvagem. Os peptídios bioativos assim identificados são inerentemente resistentes a proteases e peptidases. Também são fornecidos peptídios bioativos estabilizados por um grupo estabilizante no término-<B>N<D>, no térmico-C ou em ambos. O grupo estabilizante pode adquirir a forma de uma proteína estável pequena, tal como a proteína Rop, glutationa sulfotransferase, tiorredoxina, proteína de ligação à maltose ou glutationa redutase, ou um ou mais resíduos de prolina.
BR9914519-7A 1998-10-13 1999-10-12 Peptìdios bioativos estabilizados e métodos de identificação, sìntese e uso BR9914519A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10401398P 1998-10-13 1998-10-13
US11215098P 1998-12-14 1998-12-14
PCT/US1999/023731 WO2000022112A1 (en) 1998-10-13 1999-10-12 Stabilized bioactive peptides and methods of identification, synthesis and use

Publications (1)

Publication Number Publication Date
BR9914519A true BR9914519A (pt) 2001-07-03

Family

ID=26801102

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9914519-7A BR9914519A (pt) 1998-10-13 1999-10-12 Peptìdios bioativos estabilizados e métodos de identificação, sìntese e uso

Country Status (11)

Country Link
US (2) US6818611B1 (pt)
EP (1) EP1121425B1 (pt)
JP (1) JP2002534059A (pt)
KR (1) KR20020002354A (pt)
AT (1) ATE298796T1 (pt)
AU (1) AU773428B2 (pt)
BR (1) BR9914519A (pt)
CA (1) CA2346122C (pt)
DE (1) DE69926009D1 (pt)
MX (1) MXPA01003770A (pt)
WO (1) WO2000022112A1 (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6818611B1 (en) 1998-10-13 2004-11-16 University Of Georgia Research Foundation, Inc. Stabilized bioactive peptides and methods of identification, synthesis and use
US20030190740A1 (en) 1998-10-13 2003-10-09 The University Of Georgia Research Foundation, Inc Stabilized bioactive peptides and methods of identification, synthesis, and use
US7601691B2 (en) * 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
US20040266673A1 (en) * 2002-07-31 2004-12-30 Peter Bakis Long lasting natriuretic peptide derivatives
EP1179012B2 (en) * 1999-05-17 2009-07-15 ConjuChem Biotechnologies Inc. Long lasting fusion peptide inhibitors of viral infection
WO2002095076A2 (en) * 2001-05-23 2002-11-28 Kabushiki Kaisha Toyota Chuo Kenkyusho Modified polypeptides having protease-resistance and/or protease-sensitivity
ATE295370T1 (de) * 2001-05-31 2005-05-15 Conjuchem Inc Langwirkende fusionspeptid-inhibitoren für hiv- infektion
US7919269B2 (en) * 2001-09-26 2011-04-05 Intrexon Corporation Whitefly ecdysone receptor nucleic acids, polypeptides, and uses thereof
US6916904B2 (en) 2002-04-24 2005-07-12 Zolaris Biosciences, Llc Inhibition of immune complex formation
DK1648933T3 (da) * 2003-07-25 2009-09-07 Conjuchem Biotechnologies Inc Langvarige insulinderivater og fremgangsm der
AU2005221187B2 (en) 2004-03-10 2011-09-01 Trinity Therapeutics, Inc. Method for inhibiting immune complex formation in a subjetc
EP1747233A4 (en) * 2004-05-06 2007-04-25 COMPOUNDS FOR SPECIFIC VIRAL TARGET
GB0505420D0 (en) * 2005-03-16 2005-04-20 Isogenica Ltd Stable ligand selection method
WO2008047241A2 (en) * 2006-10-16 2008-04-24 Conjuchem Biotechnologies Inc. Modified corticotropin releasing factor peptides and uses thereof
US20090099074A1 (en) * 2007-01-10 2009-04-16 Conjuchem Biotechnologies Inc. Modulating food intake
US20090088378A1 (en) * 2007-01-12 2009-04-02 Omar Quraishi Long lasting inhibitors of viral infection
CA2687700A1 (en) * 2007-05-16 2008-11-27 Conjuchem Biotechnologies Inc. Cysteic acid derivatives of anti-viral peptides
US20090054332A1 (en) * 2007-06-21 2009-02-26 Conjuchem Biotechnologies, Inc. Thombopoietin peptide conjugates
EP2219666A4 (en) * 2007-11-15 2011-05-25 Univ North Carolina PROSTATE ACID PHOSPHATASE FOR THE TREATMENT OF PAIN
US20110039765A1 (en) * 2008-04-17 2011-02-17 Connor Ruth I Bioactive Molecules Produced by Probiotic Bacteria
MX2011000647A (es) 2008-07-18 2011-09-29 Trinity Therapeutics Inc Metodos para el tratamiento de infecciones por fiebre de dengue mediadas por el sistema inmunitario e intensificacion dependiente de anticuerpos de infecciones por fiebre de dengue, incluyendo fiebre hemorragica de dengue y sindrome de choque de deng
US20110239334A1 (en) * 2008-08-25 2011-09-29 Dow Agrosciences Llc Nematode-resistant plants, and modified bacillus thuringiensis cry genes and proteins
WO2011068801A2 (en) 2009-12-01 2011-06-09 The Rockefeller University Methods for identifying compounds that modulate ion channel activity of a kir channel
WO2013089252A1 (ja) * 2011-12-14 2013-06-20 国立大学法人 高知大学 ヘルパーｔ細胞誘導性ポリペプチドの改変
WO2014056199A1 (zh) * 2012-10-12 2014-04-17 清华大学 多肽的产生和纯化方法
WO2015003136A1 (en) * 2013-07-05 2015-01-08 The University Of Chicago Expression profiling reveals cathepsins involved in secretory vesicle maturation in tetrahymena thermophila
WO2015015448A2 (en) * 2013-07-31 2015-02-05 Rinat Neuroscience Corp. Engineered polypeptide conjugates
CA2943228C (en) 2014-03-20 2023-03-14 Bristol-Myers Squibb Company Stabilized fibronectin based scaffold molecules
CN108026149B (zh) * 2015-08-17 2022-04-29 美国陶氏益农公司 工程化的cry6a杀虫蛋白
CN108118058B (zh) * 2017-12-29 2021-06-29 苏州金唯智生物科技有限公司 一种改进的启动子及其应用
CN108118059B (zh) 2017-12-30 2021-03-19 苏州金唯智生物科技有限公司 一种改进的启动子及其组成的载体和应用
WO2020048996A1 (en) 2018-09-06 2020-03-12 ETH Zürich Self-assembling globular proteins and uses thereof

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8314362D0 (en) 1983-05-24 1983-06-29 Celltech Ltd Polypeptide and protein products
DE3328793A1 (de) 1983-08-10 1985-02-28 Hoechst Ag, 6230 Frankfurt Herstellung von sekretin
US4732864A (en) * 1983-10-06 1988-03-22 E. I. Du Pont De Nemours And Company Trace-labeled conjugates of metallothionein and target-seeking biologically active molecules
US4987070A (en) * 1987-03-04 1991-01-22 Suntory Limited Use of a 97 amino acid leader sequence from the E. coli B-galactosidase gene for the production of hanp and hptc as fusion proteins
GB8725529D0 (en) 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides
JPH0191566U (pt) * 1987-12-07 1989-06-15
US5759802A (en) * 1988-10-26 1998-06-02 Tonen Corporation Production of human serum alubumin A
US5096815A (en) 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
US5766883A (en) 1989-04-29 1998-06-16 Delta Biotechnology Limited Polypeptides
US5445954A (en) * 1989-05-24 1995-08-29 The Johns Hopkins University System for automatic gene amplification and expression
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
FR2650598B1 (fr) 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
NZ236819A (en) * 1990-02-03 1993-07-27 Max Planck Gesellschaft Enzymatic cleavage of fusion proteins; fusion proteins; recombinant dna and pharmaceutical compositions
US5792831A (en) 1990-02-08 1998-08-11 Magainin Pharmaceuticals Inc. Analogues of magainin peptides containing D-amino acids
US5217889A (en) 1990-10-19 1993-06-08 Roninson Igor B Methods and applications for efficient genetic suppressor elements
US5292646A (en) 1991-02-06 1994-03-08 Genetics Institute, Inc. Peptide and protein fusions to thioredoxin and thioredoxin-like molecules
US5646016A (en) 1991-02-06 1997-07-08 Genetics Institute, Inc. Peptide and protein fusions to thioredoxin, thioredoxin-like molecules, and modified thioredoxin-like molecules
US5270181A (en) 1991-02-06 1993-12-14 Genetics Institute, Inc. Peptide and protein fusions to thioredoxin and thioredoxin-like molecules
US5212083A (en) 1991-07-26 1993-05-18 Board Of Regents, The University Of Texas System Sequence for stabilizing proteins in bacteria
US5302519A (en) * 1991-09-09 1994-04-12 Fred Hutchinson Cancer Research Center Method of producing a Mad polypeptide
FR2686900B1 (fr) * 1992-01-31 1995-07-21 Rhone Poulenc Rorer Sa Nouveaux polypeptides ayant une activite de stimulation des colonies de granulocytes, leur preparation et compositions pharmaceutiques les contenant.
FI92601C (fi) * 1992-03-11 1994-12-12 Marja Makarow Menetelmä hyötyproteiinien erittämiseksi hiivoista
GB9210337D0 (en) 1992-05-14 1992-07-01 Univ Court Of The University O Feline leukaemia virus vaccine
US5654451B1 (en) 1993-01-14 2000-02-22 Magainin Pharma Amino acids and peptides having modified c-terminals and modified n-terminals
US5804553A (en) * 1994-04-05 1998-09-08 University Of California Prophenins - antibiotic peptides
US5589364A (en) 1994-07-29 1996-12-31 Magainin Pharmaceuticals Inc. Recombinant production of biologically active peptides and proteins
US5888763A (en) * 1994-12-30 1999-03-30 The Rockefeller University Peptides specific for the first Crk-SH3 domain
US5733726A (en) 1995-06-07 1998-03-31 Emory University Cytotoxicity-based genetic selection system (TOXSEL)
WO1997004110A1 (en) * 1995-07-14 1997-02-06 Somatogen, Inc. Methods for increasing protein expression
US5741646A (en) 1995-12-29 1998-04-21 Fox Chase Cancer Center Cell lines and methods for screening growth regulatory compounds
US5962270A (en) 1996-02-06 1999-10-05 Bionebraska, Inc. Recombinant preparation of calcitonin fragments and use thereof in the preparation of calcitonin and related analogs
AU7298398A (en) 1996-11-19 1998-06-10 Sangstat Medical Corporation Enhanced effects for hapten conjugated therapeutics
EP1046034A1 (en) * 1998-01-09 2000-10-25 Cubist Pharmaceuticals, Inc. Method for identifying validated target and assay combinations
WO1999036554A1 (en) * 1998-01-16 1999-07-22 Pharmacia & Upjohn Company An autoregulatory system for validating microbial genes as possible antimicrobial targets using a tetracycline-controllable element
AU2577699A (en) * 1998-02-06 1999-08-23 Human Genome Sciences, Inc. Human serine protease and serpin polypeptides
WO1999053079A1 (en) * 1998-03-03 1999-10-21 Cubist Pharmaceuticals, Inc. Regulable gene expression in gram-positive bacteria
US6630197B1 (en) * 1998-05-06 2003-10-07 Regents Of The University Of California Inhibition of sulfate-reducing-bacteria-mediated degradation using bacteria which secrete antimicrobials
US6057129A (en) * 1998-06-19 2000-05-02 The Rockfeller University Clock gene and methods of use thereof
US6406921B1 (en) * 1998-07-14 2002-06-18 Zyomyx, Incorporated Protein arrays for high-throughput screening
US6180343B1 (en) * 1998-10-08 2001-01-30 Rigel Pharmaceuticals, Inc. Green fluorescent protein fusions with random peptides
US6818611B1 (en) * 1998-10-13 2004-11-16 University Of Georgia Research Foundation, Inc. Stabilized bioactive peptides and methods of identification, synthesis and use
US20030190740A1 (en) * 1998-10-13 2003-10-09 The University Of Georgia Research Foundation, Inc Stabilized bioactive peptides and methods of identification, synthesis, and use
US20010056075A1 (en) 1999-07-19 2001-12-27 Jeno Gyuris Chimeric polypeptides of serum albumin and uses related thereto
EP1240337B1 (en) 1999-12-24 2006-08-23 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
EP2213743A1 (en) 2000-04-12 2010-08-04 Human Genome Sciences, Inc. Albumin fusion proteins

Also Published As

Publication number Publication date
AU773428B2 (en) 2004-05-27
CA2346122C (en) 2013-01-22
DE69926009D1 (de) 2005-08-04
AU6427099A (en) 2000-05-01
EP1121425B1 (en) 2005-06-29
ATE298796T1 (de) 2005-07-15
CA2346122A1 (en) 2000-04-20
WO2000022112A1 (en) 2000-04-20
JP2002534059A (ja) 2002-10-15
US6818611B1 (en) 2004-11-16
WO2000022112A9 (en) 2000-08-24
US7122516B2 (en) 2006-10-17
KR20020002354A (ko) 2002-01-09
MXPA01003770A (es) 2002-05-06
US20040235091A1 (en) 2004-11-25
EP1121425A1 (en) 2001-08-08

Similar Documents

Publication Publication Date Title
BR9914519A (pt) Peptìdios bioativos estabilizados e métodos de identificação, sìntese e uso
WO2004011485A3 (en) Stabilized bioactive peptides and methods of identification, synthesis, and use
CZ20011671A3 (cs) Peptidová nosná skupina pro transport
PT670898E (pt) Polipeptidos de multiplas mutacoes de interleucina-3 (il-3)
WO2003027246A3 (en) Antagonists
ATE338121T1 (de) Von muc-1 abgeleitete peptide
DE69836638D1 (de) Peptidanaloga abgeleitet vom tumornekrose-faktor-rezeptor
DK0692025T3 (da) Gærceller, der er konstrueret således, at de producerer surrogater for proteiner i feromonsystemet, og anvendelser deraf
DE69838143D1 (de) Antimikrobielle peptide
CO5050400A1 (es) Proteina de chlamydia, secuencia de genes y anticuerpos para ello
ATE406439T1 (de) Eukaryontische signalsequenzen für polypeptid- expressions- und polypeptid- präsentationsbibliotheken
AU2003242817A1 (en) Cosmetic or pharmaceutical composition containing peptides
AU2650597A (en) Novel fas antigen derivatives
AU1207301A (en) Stabilized proteins
DK0896615T3 (da) Peptid fra opløselig form af acetylcholinesterase, der er aktivt som calcium-kanal-modulator
IT1307309B1 (it) Peptidi stabilizzanti, polipeptidi ed anticorpi che li comprendono.
ES2172044T3 (es) Supresion de la proliferacion de celulas t usando fragmentos peptidicos de proteina basica de mielina.
WO2002059293A3 (en) Process and compositions for peptide, protein and peptidomimetic synthesis
WO2002008716A3 (fr) Procede de criblage de peptides utilisables en immunotherapie
DK1681298T3 (da) Fremgangsmåder til oprensning af særdeles anioniske proteiner
DK0783521T3 (da) Polypeptidforbindelser indeholdende D-2-alkyltryptophan, hvilke er i stand til at fremme frigivelsen af væksthormon
WO2000058465A3 (en) Flint polypeptide analogs
WO2004022587A3 (en) A pair of polypeptides with specific and strong interaction
EP0893501A3 (en) Ferrichrome transport atp-binding protein
WO1998038211A3 (en) Permuted hemoglobin-like proteins

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A, 8A E 9A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1962 DE 12/08/2008.